- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HHS: Some Drugs Prescribed by Barred Docs
HHS Inspector General Daniel Levinson's office audited all $185 billion in drugs that were prescribed during the first 3 years of the new prescription-drug benefit program, known in government circles as Medicare Part D, and found that a narrow share—less than 1%—was ordered by doctors prohibited from prescribing between 2006 and 2008.
Auditors pinpointed several inadequate internal controls that allowed at least $15.1 million in prohibited prescriptions to be dispensed to patients, including the CMS' past practice of not allowing its prescription-drug contractors access to a central database of prohibited prescribers. Auditors also criticized the HHS contractors' use of state indentifiers in screening databases instead of unique national provider identifier numbers.
Read more at: http://tinyurl.com/7hh94hh
Source: Modern Healthcare
In part because of past shortcomings in a centralized database, the Centers for Medicare & Medicaid Services (CMS) and its contractors that administer the Medicare prescription-drug benefit have allowed more than $15 million worth of drugs to be dispensed to patients by doctors whose past criminal activity should have barred them from prescribing, according to a new report (PDF).
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
